Article
Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Neuro-oncology - 1 Mar 2017
Nguyen HuyTram N, Lie Amy, Li Tie, Chowdhury Reshmi, Liu Fei, Ozer Byram, Wei Bowen, Green Richard M, Ellingson Benjamin M, Wang He-Jing, Elashoff Robert, Liau Linda M, Yong William H, Nghiemphu Phioanh L, Cloughesy Timothy, Lai Albert
Abstract excerpt
Background: Promoter mutation in the human telomerase reverse transcriptase gene (hTERT) occurs in ~75% of primary glioblastoma (GBM). Although the mutation appears to upregulate telomerase expression and contributes to the maintenance of telomere length, its clinical significance remains unclear. Methods: We performed hTERT promoter genotyping on 303 isocitrate dehydrogenase 1 wild-type GBM tumors treated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.